• Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).

  • May 2 2025
  • Duración: 22 m
  • Podcast

Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Takeaways

    • MASH is a significant obesity-related complication.
    • Semaglutide shows promise in treating MASH.
    • Weight loss is crucial for improving liver health.
    • Bariatric surgery remains the most effective treatment.
    • The Essence trial indicates a 63% resolution of NASH.
    • New medications are being developed for obesity treatment.
    • Early intervention is key to preventing severe liver damage.
    • Accessibility of medications is a major concern.
    • Comparative studies are essential for evaluating new treatments.
    • Future treatments may include innovative delivery methods.

    Chapters

    00:00 Introduction to MASH and Semaglutide Study

    04:29 Understanding Metabolic Dysfunction and Its Implications

    08:02 Essence Trial: Semaglutide's Impact on MASH

    12:58 Comparative Analysis of New Treatments for MASH

    17:30 The Future of Obesity Treatment and Drug Accessibility

    Join Vineyard - Dr. Spencer's online clinic

    See the study
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles